Pharmaceutical Supply Chains Face API and Industrial-Policy Risks

Bangladesh illustrates the vulnerability of pharmaceutical manufacturing that relies heavily on imported active ingredients despite strong formulation capacity. Finance costs, regulatory delays, unreliable gas access, skills shortages, and the impending loss of its least-developed-country patent waiver complicate efforts to become a second-source supplier.